<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180085</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0133</org_study_id>
    <nct_id>NCT04180085</nct_id>
  </id_info>
  <brief_title>Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)</brief_title>
  <acronym>BELACOEUR</acronym>
  <official_title>Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart transplantation (TC) is the standard treatment for terminal heart failure. Chronic&#xD;
      kidney disease (CKD) is a common complication responsible for increased mortality and&#xD;
      morbidity. The main risk factors for progression to CKD are advanced age, pre-transplantation&#xD;
      CKD, degradation of glomerular filtration rate (GFR) in the first year post-transplantation,&#xD;
      and nephrotoxicity of calcineurin inhibitors (CNI).&#xD;
&#xD;
      Indeed, these molecules (cyclosporin and tacrolimus), the cornerstone of immunosuppressive&#xD;
      treatment, have nephrotoxic effects in the short term (by a hemodynamic effect) and in the&#xD;
      long term (by a pro-fibrosin effect).&#xD;
&#xD;
      In renal transplantation (TR), belatacept, a costimulation-inhibiting molecule, used de novo,&#xD;
      without CNI, with induction by anti-receptor antibody of Interleukines 2, preserves kidney&#xD;
      function. Despite this great advantage, its development is still hampered by a higher number&#xD;
      of rejections compared to the CNI group in this originator study. Based on the experience&#xD;
      gained in TR, which has since validated its use, the hypothesis is that in heart&#xD;
      transplantation, belatacept (Nulojix) combined with minimization of CNI (with induction by&#xD;
      antilymphocyte serum), could significantly improve glomerular filtration rate (GFR) in&#xD;
      patients at risk of CKD (by removing them from dialysis and possible kidney transplantation)&#xD;
      without increasing the risk of rejection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance</measure>
    <time_frame>12 months</time_frame>
    <description>Determination of plasma creatinine and calculation of clearance according to the formula CKD EPI (Chronic Kidney Disease - Epidemiology Collaboration) at 3 months and 12 months post heart transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial biopsies</measure>
    <time_frame>12 months</time_frame>
    <description>Myocardial biopsies between 3 months and 12 months post Cardiac Transplantation to check the risk of rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-human leukocyte antigen antibody assay</measure>
    <time_frame>12 months</time_frame>
    <description>To check the risk of rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose and glycated haemoglobin (HBA1C)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of the New Onset Diabetes After Transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the mortality specific to 12 months post cardiac transplantation (Estimate: percentage of patients who died at 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dialysis sessions</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the use of renal replacement therapy between 3 months and 12 months after Cardiac Transplantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Heart Transplant Failure</condition>
  <arm_group>
    <arm_group_label>BELATACEPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept Injection</intervention_name>
    <description>9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft</description>
    <arm_group_label>BELATACEPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cardiac transplant patients for 3 months Over 18 years of age No Donor Specific Antibodies&#xD;
        at inclusion (positive threshold average fluorescence intensity (MFI)&gt; 2000) Having a GFR&#xD;
        (DFG in french) is the single best indicator of overall renal function &lt; 30ml/min&#xD;
        calculated according to the formula CKD EPI or a decrease in GFR of more than 50% between&#xD;
        the day of the heart transplant and 3 months, stable for 15 days.&#xD;
&#xD;
        Induction treatment with anti-lymphocyte serum Virus d'Epstein-Barr positive serology&#xD;
        Having signed the consent after receiving informed information Negative pregnancy test for&#xD;
        patients of childbearing age, and agreement to use effective contraception throughout the&#xD;
        study and 6 weeks after the end of the study Having no difficulty in understanding and&#xD;
        communicating with the investigator and his representatives Beneficiaries of a Social&#xD;
        Security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The criteria for non-inclusion are:&#xD;
&#xD;
        2nd heart transplant or other solid organ transplant History of rejections Cellular or&#xD;
        humoral rejection at myocardial biopsy of 3 months post Transplantation Cardiac Current&#xD;
        viral infection of type cytomegalovirus, Virus d'Epstein-Barr, hepatitis C virus, hepatitis&#xD;
        V virus.....&#xD;
&#xD;
        Human immunodeficiency virus positive serology Ongoing participation in another clinical&#xD;
        study Any clinical condition that the investigator considers incompatible with the conduct&#xD;
        of the study under acceptable safety conditions: (in particular, progressive infection,&#xD;
        progressive cardiovascular complication, progressive neoplastic disease) Inability of the&#xD;
        patient to comply with study procedures Pregnant or breastfeeding women Person under&#xD;
        guardianship, curators or safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claire GARANDEAU, PH</last_name>
    <phone>0240087453</phone>
    <email>claire.garandeau@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karine Nubret</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine Nubret</last_name>
      <phone>0556795679</phone>
      <email>Karine.nubret@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laurent Sebbag</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Sebbag</last_name>
      <phone>06.99.38.58.23</phone>
      <email>laurent.sebbag@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Claire Garandeau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Garandeay</last_name>
      <phone>0240087453</phone>
      <email>claire.garandeau@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bertrand Lelong</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Lelong</last_name>
      <phone>0299284118</phone>
      <email>bernard.lelong@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emmanuelle Vermes</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Vermes</last_name>
      <phone>0247475918</phone>
      <email>e.vermes@chu-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

